Keryx Biopharmaceuticals to Present at Cowen and Company’s 36th Annual Health Care Conference on Monday, March 7

BOSTON, March 01, 2016 -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease, today announced it will present at the Cowen and Company 36^th Annual Health Care Conference in Boston, MA on Monday, March 7, 2016 at 3:20 p.m. EST.

A live audio webcast of the presentation will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under the “webcasts and presentations” page. An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, with headquarters in Boston, is focused on bringing innovative medicines to market for people with renal disease. In December 2014, the company launched its first FDA-approved product, Auryxia™ (ferric citrate) for the control of elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on dialysis, in the United States. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex) for the control of hyperphosphatemia in adults with non-dialysis and dialysis-dependent chronic kidney disease. For more information about Keryx, please visit www.keryx.com

KERYX CONTACT:
Lora Pike
Senior Director, Investor Relations
T: 617-466-3511
[email protected]